<DOC>
	<DOCNO>NCT00817843</DOCNO>
	<brief_summary>The purpose study investigate whether low-dose simvastatin combination ezetimibe comparison high-dose simvastatin alone , beneficial effect function endothelium oral fat load patient metabolic syndrome .</brief_summary>
	<brief_title>The PostprAndial eNdothelial Function After Combination Ezetimibe simvAstatin Study</brief_title>
	<detailed_description>Metabolic syndrome define group cardiovascular risk factor mainly drive epidemic obesity . High blood lipid level meal may important risk factor cardiovascular disease . In study investigate whether simvastatin combination ezetimibe vs. simvastatin alone , beneficial effect lipid level meal , importantly , whether measure difference function endothelium . In small pilot study already find combination beneficial effect comparison simvastatin alone . Now want solidify finding large study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patient diagnosis metabolic syndrome accord modified 2005 AHA/NHLBI Scientific Statement least : Abdominal obesity define : *Males : waist circumference &gt; 102cm Females : waist circumference &gt; 88cm two follow 4 criterion : Triglycerides &gt; 150 mg/dL HDL Cholesterol Males : HDLC &lt; 40 mg/dL Females : HDLC &lt; 50 mg/dL Blood pressure Systolic Blood Pressure ≥130 mmHg Diastolic Blood Pressure ≥85 mmHg Fasting glucose ≥ 100 mg/dL 2 . Patient understand study procedure , alternative treatment available , risk involve study , voluntarily agree participate give write informed consent . 3 . Patient male female 1879 year age day sign informed consent . 4 . Patient nonsmoker . 5 . Patient willing maintain stable diet duration study . 6 . Patient postmenopausal female receive hormone therapy ( include cyclic noncyclical hormone replacement therapy estrogen antagonist/agonist ) . Postmenopausal status define ( 1 ) menses ≥1 year &lt; 3 year confirm FSH level elevate postmenopausal range ( define designate laboratory ) ( 2 ) menses least 3 year . 7 . Patient naïve lipidlowering therapy . Naïve define treated statin , fibrate ezetimibe 3 month Visit 1 ( Week 2 ) 8 . Patient baseline fast LDLC level ≥ 100 mg/dL &lt; 220 mg/dL , TG level &lt; 400 mg/dL . EXCLUSION CRITERIA : 1 . Patient BMI &gt; 35 . 2 . Patient hypersensitivity intolerance ezetimibe simvastatin component medication , latex . 3 . Patient routinely consume 14 alcoholic drink per week . 4 . Patient currently participate participate study investigational compound device within 30 day sign informed consent . 5 . Patient smoke history &gt; 10 packyears ( 1 packyear = least 20 cigarette per day year ) OR patient smoke within 3 month prior Visit 1 ( Week 2 ) . 6 . Patient exclusionary laboratory value Visit 1 ( Week 2 ) list table : liver transaminase ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] ) &gt; 1.5 X ULN active liver disease Serum glucose &gt; 7.0 mmol/L Creatine kinase ( CK ) &gt; 2 X ULN Albumin : creatinine ratio &gt; 34 TSH &lt; 0.3 mcIU/mL &gt; 5.0 mcIU/mL 7 . Patient history current evidence condition , therapy , lab abnormality circumstance might confound result study , interfere patient 's participation full duration study , best interest patient participate . 8 . It possible obtain FMD measurement sufficient quality screening ( Visit 1 ) 9 . Patient congestive heart failure , atherosclerotic vascular disease acute chronic coronary heart disease . 13 . Patient partial ileal bypass , gastric bypass , gastric banding , celiac disease significant intestinal malabsorption . 15 . Patient untreated uncontrolled hypertension systolic blood pressure &gt; 160 mm Hg diastolic &gt; 100 mm Hg Visit 1 ( Week 2 ) . ( Patients untreated hypertension office BP Visit 1 Visit 2 average 160/100 less enrol ) . Patients use blood pressurelowering medication exclude . 16 . Patient estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73 m2 base 4variable MDRD 17 . Patient uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins Visit 1 ( Week 2 ) . 18 . Patient diabetes mellitus define history diabetes fast serum glucose &gt; 126 mg/dL . For full exclusion criterion , please check protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Postprandial hypertriglyceridemia</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Flow mediate dilatation</keyword>
	<keyword>EndoPAT</keyword>
	<keyword>Simvastatin</keyword>
	<keyword>Ezetimibe</keyword>
</DOC>